About 32 results found for searched term "3-TYP" (0.057 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M8978 | 3-TYP | Sirtuin |
| 3-(1H-1,2,3-triazol-4-yl) pyridine; 3TYP | ||
| 3-TYP is a selective SIRT3 inhibitor, more potent over SIRT1 and SIRT2, with IC50 values of 88 nM, 92 nM, 16 nM for SITR1, SIRT2, SIRT3, respectively. | ||
| M53429 | Bax BH3 peptide (55-74), wild type | Apoptosis |
| Bax BH3 peptide (55-74), wild type is a 20-amino acid Bax BH3 peptide (Bax 1) capable of inducing apoptosis in a variety of cell line models. | ||
| M1794 | SB431542 | ALK |
| SB-431542 | ||
| SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). | ||
| M1865 | Bevirimat | HIV Protease |
| BVM, MPC-4326, PA-457 | ||
| Bevirimat (BVM), also known as PA-457 or MPC-4326, is a novel Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor. | ||
| M1873 | LDN-193189 | ALK |
| DM-3189; LDN193189 | ||
| LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. | ||
| M2000 | GW788388 | TGF-β Receptor |
| GW788388 is a potent selective inhibitor of TGF-beta type I receptor and ALK5 with IC50 values of 0.093 and 0.018 μM. | ||
| M2016 | LY364947 | TGF-β Receptor |
| HTS 466284 | ||
| LY364947 is a selective small molecule inhibitor of the TGFβ type I receptor kinase with IC50 of 59 nM. | ||
| M2106 | Azilsartan | Angiotensin Receptor |
| TAK-536 | ||
| Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. | ||
| M2108 | SB-525334 | TGF-β Receptor |
| SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM. | ||
| M2139 | Sulfatinib | VEGFR/PDGFR |
| HMPL-012; Surufatinib | ||
| Sulfatinib is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1). | ||
| M2203 | Elbasvir | HCV Protease |
| MK-8742 | ||
| Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) replication complex inhibitor, with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively. | ||
| M2522 | Ciproxifan | Histamine Receptor |
| FUB-359 | ||
| Ciproxifan is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes. | ||
| M2805 | LDN-193189 dihydrochloride | ALK |
| DM-3189 dihydrochloride | ||
| LDN-193189 dihydrochloride is a selective BMP signaling inhibitor, and inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, 200-fold selectivity for BMP versus TGF-β. | ||
| M2891 | NSC 319726 | Cuproptosis |
| NSC-319726; ZMC1 | ||
| NSC 319726 is a p53(R175) mutant activator that inhibits the growth of p53(R175) mutant cells and acts on p53(R175) mutant cells with IC50 of 8 nM, which has no inhibition on p53 wild-type cells. NSC 319726 is a potent copper ion-carrier that can be used in cuproptosis studies. | ||
| M3058 | Terfenadine | Potassium Channel |
| (±)-Terfenadine; MDL-991 | ||
| Terfenadine is an antihistamine compound that is normally fully metabolized in the liver by the cytochrome P450 CYP3A4 subtype enzyme into the active form fexofenadine. | ||
| M3125 | VU 0364770 | GluR |
| VU 0364770 is a positive allosteric modulator(PAM) of mGlu4 with EC50 of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes. | ||
| M3126 | VU 0357121 | GluR |
| VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes. | ||
| M3229 | PR-104A | DNA/RNA Synthesis |
| PR-104A is a corresponding alcohol that is systemically converted from PR-104 and a hypoxia-targeted anticancer agent with IC50 of 153 and 60 μM for wild-type CHO AA8 under aerobic and anoxic conditions. | ||
| M3275 | Irbesartan | Angiotensin Receptor |
| SR-47436; BMS-186295 | ||
| Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM. | ||
| M3278 | MK-5172 (Grazoprevir) | HCV Protease |
| Grazoprevir; MK5172 | ||
| MK-5172 is a novel NS3/4, a protease inhibitor for chronic HCV infection (Enzyme Ki for genotype1b, 2a, 2b and 3a at ＜0.02, 0.15, 0.02 and 0.7 nM, respectively). | ||
| M3321 | GSK1292263 | GPR/FFAR |
| GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. | ||
| M3381 | Nevirapine | Reverse Transcriptase |
| BI-RG 587; NSC 641530; NVP | ||
| Nevirapine (NSC 641530) is a potent, specific non-nucleoside reverse transcriptase inhibitor (NNRTIs) that non-competitively inhibits human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with a Ki of 220 nM. Nevirapine (NSC 641530) can be used in AIDS-related researchs. | ||
| M3435 | Saxagliptin | Dipeptidyl Peptidase |
| BMS-477118 | ||
| Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active inhibitor of dipeptidyl peptidase 4 (DPP-4) (Ki = 0.6-1.3 nM). Saxagliptin can be used in type 2 diabetes studies. | ||
| M3445 | ADX-47273 | GluR |
| ADX47273 is a potent and specific mGlu5 positive allosteric modulator(PAM) with EC50 of 0.17 μM, showing no activity at other mGlu subtypes. | ||
| M3481 | WAY-100635 Maleate | 5-HT Receptor |
| WAY-100635 maleate is a potent, selective 5-HT1A receptor antagonist with an IC50 value of 0.91 nM, a Ki value of 0.39 nM, and a pIC50 of 8.87, which is more than 100-fold more selective than for use at the other 5-HT receptor subtypes and major neurotransmitter receptors. In addition, WAY-100635 maleate is a potent dopamine D4 receptor agonist. | ||
| M3613 | NP118809 | Calcium Channel |
| 39-1B4, NP-118809 | ||
| NP-118809 (39-1B4) is a potent N-type calcium channel blockers (IC50= 0.11 uM) ; good selectivity over L-type calcium channels. | ||
| M3680 | GS-9451 | HCV Protease |
| GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients infected with HCV genotype 1 (GT 1). | ||
| M3915 | Catechin | COX |
| (+)-Catechin; Cianidanol | ||
| Catechin (Cianidanol) is a flavan-3-ol, a type of natural phenol and antioxidant. Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. | ||
| M3950 | APD668 | GPR/FFAR |
| APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively. APD668 pairs are divided by CYP2C9 (KiNone of the five major CYP subtypes other than =0.1 μM) had no significant inhibitory effect. APD668 can be used for research on steatohepatitis and diabetes. | ||
| M3957 | Mitiglinide calcium | Potassium Channel |
| KAD-1229,S21403 | ||
| Mitiglinide (KAD 1229, S 21403), a derivative of benzysuccinic acid, is a potassium channel antagonist developed with Kissei for the study of type 2 diabetes. | ||
| M3975 | Lorlatinib (PF-06463922) | ALK |
| PF-06463922 | ||
| Lorlatinib (PF-06463922) is an oral active, selective, brain osmotic and ATP-competitive ROS1/ALK inhibitor. The Ki of Lorlatinib for ROS1, wild-type ALK and ALK(L1196M) were <0.025 nM, <0.07 nM and 0.7 nM, respectively. Lorlatinib has anticancer activity. | ||
| M4138 | Deucravacitinib (BMS-986165) | JAK |
| BMS986165 | ||
| Deucravacitinib (BMS-986165) is a first-in-class, selective, orally bioavailable inhibitor of TYK2 transitions.Deucravacitinib selectively binds the TYK2 pseudokinase (JH2) structural domain with an IC50 of 1.0 nM and a Ki value of 0.02 nM. Deucravacitinib (BMS-986165) blocks receptor-mediated Tyk2 activation by stably regulating the JH2 structural domain. deucravacitinib also inhibits the IL-12/23 and type I IFN pathways. deucravacitinib may be used in psoriasis research. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
